Anorectal sexually transmitted infections are emerging as an increasingly important global health challenge, even as testing becomes more widely available. A new review in Nature Reviews Gastroenterology & Hepatology examines how infections caused primarily by Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum are spreading, persisting and evading detection. The analysis describes a troubling paradox: improved molecular diagnostics can identify more infections than ever before, yet many cases remain undiagnosed because they produce no noticeable symptoms.

The burden is especially pronounced among men who have sex with men, a population in which anorectal infections can be more common than infections of the urethra. Rectal chlamydia, gonorrhoea and syphilis may occur without pain, discharge, bleeding or other signs that would prompt a person to seek medical care. This silent pattern allows infections to persist and increases the likelihood of onward transmission. It also means that testing based only on urine or genital samples can miss infections located exclusively in the rectum.

The biological environment of the anorectal tract helps explain why these infections can remain hidden. The rectum contains a complex epithelial surface, a dense microbial community and an immune system adapted to tolerate constant exposure to foreign substances. Bacteria that colonize this tissue can interact with epithelial cells, mucus and local immune defenses in ways that differ from infections at urogenital sites. According to the review, pathogen adaptation and relatively attenuated local inflammatory responses may prevent immune activity from reaching the threshold required to cause recognizable symptoms, even while bacterial replication and transmission continue.

Chlamydia illustrates the complexity of this process. The organism has a distinctive intracellular life cycle, entering epithelial cells and alternating between infectious elementary bodies and replicative reticulate bodies. Within rectal tissue, this cycle can support persistent infection while limiting the immediate inflammatory signals that would otherwise produce symptoms. Gonorrhoea, by contrast, is caused by a bacterium capable of rapid genetic adaptation, including changes in surface proteins and mechanisms that help it evade immune recognition. These adaptations contribute to repeated infections and complicate the development of durable immunity.

Syphilis adds another layer of difficulty because its causative organism, T. pallidum, can disseminate beyond the initial site of infection. Rectal exposure may produce lesions that are internal, painless or difficult to observe, allowing infection to progress unnoticed. Without diagnosis and treatment, syphilis can move through distinct clinical stages and eventually affect multiple organ systems. The overlap between asymptomatic anorectal infection and broader systemic disease makes targeted screening essential, particularly for people with ongoing exposure risks or previous sexually transmitted infections.

Modern nucleic acid amplification tests have transformed the detection of anorectal infections. These assays identify pathogen-specific genetic material from rectal swabs and can detect infections that conventional culture or symptom-based evaluation would miss. Their high analytical sensitivity has expanded the known burden of disease and enabled more effective screening programs. However, molecular detection also creates an important interpretive problem: the presence of bacterial DNA or RNA does not always prove that viable, transmissible organisms remain. Genetic material may persist after treatment or after bacterial death, making it difficult to distinguish active infection from residual signals.

The review also emphasizes that access to testing remains uneven. Laboratory-based molecular assays may require trained personnel, specialized equipment and transport systems that are unavailable in many settings. Point-of-care tests could shorten the time between sampling, diagnosis and treatment, reducing loss to follow-up and limiting transmission. Yet such technologies must achieve sufficient sensitivity and specificity for anorectal specimens, where bacterial loads, sampling quality and mixed infections can vary. Faster diagnosis must also be paired with clear clinical guidance to prevent unnecessary antibiotic use.

Treatment is becoming more complicated as antimicrobial resistance advances, most notably in gonorrhoea. N. gonorrhoeae has acquired resistance to multiple antibiotic classes through genetic mutations, mobile genetic elements and mechanisms that reduce drug penetration or actively expel antibiotics from the cell. This narrowing therapeutic window increases the importance of culture and susceptibility testing when treatment failure is suspected. It also reinforces the need for surveillance systems that can detect resistance trends before they become widespread and for stewardship strategies that preserve the effectiveness of remaining therapies.

Prevention research is developing alongside new diagnostic and treatment approaches. Doxycycline post-exposure prophylaxis, commonly known as doxy-PEP, has been shown to substantially reduce the incidence of chlamydia and syphilis in selected populations when taken after sex under medical guidance. Its impact on gonorrhoea is less consistent, in part because resistance to tetracycline-class antibiotics is already common in many gonococcal strains. The broader use of doxy-PEP therefore requires careful monitoring for antimicrobial resistance, changes in the microbiome and possible effects on other bacterial infections.

Artificial intelligence may also contribute to future control strategies by helping identify people most likely to benefit from screening, interpreting clinical and laboratory data, and improving public-health surveillance. However, algorithms depend on the quality and representativeness of the data used to train them. Systems developed from narrowly defined clinical populations may perform poorly in communities with different epidemiological patterns, access to care or testing behaviors. The review concludes that controlling anorectal sexually transmitted infections will require more than advanced technology: it will depend on integrated screening, accessible care, responsible antibiotic use and research that reflects the diversity of real-world sexual health settings.

Subject of Research: Anorectal bacterial sexually transmitted infections, including chlamydia, gonorrhoea and syphilis; their epidemiology, pathogenesis, diagnosis, treatment and prevention.

Article Title: Mechanisms, management and prevention of anorectal sexually transmitted infections

Article References: Latt, P.M., Kong, F.Y.S., Khosropour, C.M. et al. “Mechanisms, management and prevention of anorectal sexually transmitted infections.” Nature Reviews Gastroenterology & Hepatology (2026). https://doi.org/10.1038/s41575-026-01232-6

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01232-6

Keywords: anorectal sexually transmitted infections, chlamydia, gonorrhoea, syphilis, men who have sex with men, molecular diagnostics, antimicrobial resistance, doxycycline post-exposure prophylaxis, artificial intelligence, sexual health

The human microbiome, an intricate ecosystem of microorganisms residing predominantly on mucosal surfaces, plays a pivotal role in modulating immunity, metabolism, and barrier functions. The oral, gastrointestinal, and genital microbiomes form dynamic interrelated axes that can be significantly influenced by pharmacological agents, including antibiotics. The administration of doxycycline as a prophylactic measure introduces a substantial antimicrobial pressure, raising crucial questions about its collateral effects on the stability and diversity of microbial populations, and by extension, on host susceptibility to infections.

Knodel and colleagues executed a comprehensive multi-omics investigation to characterize the microbiome alterations induced by doxyPrEP in MSM populations who are concurrently utilizing HIV PrEP. Their methodology combined longitudinal sampling with advanced metagenomic sequencing and functional profiling to capture not only taxonomic shifts but also metabolic and resistance gene dynamics within the microbiota. This holistic approach allowed for an unprecedented resolution in assessing how sustained doxycycline exposure reshapes microbial consortia over time.

One salient finding of the study is the notable decrease in microbial diversity within the oropharyngeal and rectal sites following initiation of doxyPrEP. Diversity is often correlated with ecosystem resilience; therefore, a contraction may denote increased vulnerability to colonization by opportunistic pathogens or dysbiosis-associated complications. The authors observed a selective diminution of commensal bacterial taxa, particularly those implicated in maintaining mucosal health, which could bear long-term implications for mucosal immunity and microbial equilibrium.

Parallel to taxonomic perturbations, the researchers identified an upregulation of antimicrobial resistance genes (ARGs), particularly those conferring resistance to tetracyclines and related classes. This elevation in resistome complexity underscores the unintended consequence of prophylactic antibiotic use: the facilitation of resistance gene dissemination and potential compromise of future therapeutic efficacies. Such findings underscore the delicate balance between prophylactic benefits and the overarching public health risks posed by antimicrobial resistance.

The functional metagenomic analyses further revealed shifts in metabolic pathways, including those involved in the synthesis of key short-chain fatty acids (SCFAs) known to regulate inflammation and epithelial barrier integrity. Altered SCFA profiles might translate to modified mucosal immunological landscapes, potentially exacerbating or mitigating susceptibility to various STIs beyond the antibacterial protective effect of doxycycline itself.

Interestingly, the study also highlighted variability in microbiome responses correlated with host behavioral and clinical variables. For instance, adherence levels to doxyPrEP, concomitant use of other antimicrobial agents, and sexual practices modulated the degree of microbiome alteration. Such heterogeneity points to the necessity for personalized prophylactic strategies and tailored microbiome monitoring in long-term doxyPrEP users.

Despite these perturbations, the authors emphasize that doxyPrEP remains a potent tool in reducing the incidence of certain bacterial STIs, notably syphilis and chlamydia, which continue to present significant public health challenges in MSM communities globally. The prophylactic efficacy shown in controlled trials offers a compelling case for integrating doxyPrEP into broader STI prevention frameworks, particularly where conventional barrier methods and behavioral interventions are insufficient.

However, the underpinning microbial shifts revealed by this study call for a cautious approach, emphasizing continuous surveillance and adjunctive measures to mitigate the risk of resistance emergence. The authors suggest that combining doxyPrEP with microbiome-supportive interventions, such as probiotics or post-antibiotic microbiome restoration therapies, could enhance long-term outcomes and preserve microbial homeostasis.

Moreover, this research sets the stage for future investigations into the mechanistic underpinnings of how antibiotic-induced microbiome modifications affect mucosal immunology and pathogen-host interactions. In-depth exploration of host transcriptomic responses concurrent with microbiome assessments could illuminate pathways relevant to both infection susceptibility and immune tolerance under prophylactic regimens.

Emerging data from this study also underscore the importance of integrating microbiome profiling into clinical monitoring protocols for individuals on long-term doxyPrEP. Biomarkers derived from microbial composition or functional capacity may serve as early indicators of adverse ecological shifts or resistance proliferation, enabling preemptive clinical interventions.

From a broader perspective, the implications of antibiotic-based prophylaxis extend beyond individual patient outcomes, touching upon ecosystem-wide microbial resistance trajectories. Doxycycline’s role as both a therapeutic and prophylactic agent necessitates stewardship programs that balance immediate infection control benefits with sustainable resistance management across populations.

In tandem with microbiological insights, socio-behavioral factors remain critical in shaping doxyPrEP’s real-world effectiveness. Understanding patient perceptions, adherence challenges, and potential stigma associated with antibiotic prophylaxis will inform culturally sensitive education and support frameworks, crucial for optimizing uptake and impact.

Looking ahead, the intersection of precision medicine and microbiome science offers promising avenues to refine doxyPrEP strategies. Personalized profiling could identify candidates who are likely to benefit most while minimizing ecological disruption. Additionally, alternative prophylactic modalities with narrower antimicrobial spectra or non-antibiotic agents may emerge as viable options influenced by findings from such microbiome-centered research.

In summary, the study by Knodel et al. provides a seminal analysis of how doxycycline pre-exposure prophylaxis for STIs modulates the microbiome landscape in MSM populations on HIV PrEP. The delicate interplay between antimicrobial benefits and microbiological risks elucidated herein advances our understanding of prophylactic antibiotic use in sexual health and underscores the imperative for integrative approaches that preserve microbial integrity while combating infections.

As the global health community continues to grapple with rising STI incidences and the looming threat of antimicrobial resistance, studies like this serve as critical guideposts. They not only highlight the promise of novel preventive strategies but also call attention to the complexity inherent in manipulating microbial ecosystems within the human body. Ultimately, sustainable STI prevention will likely hinge on synergistic solutions that harmonize pharmacological innovation, microbiome stewardship, and patient-centered care.

Subject of Research: Impact of doxycycline pre-exposure prophylaxis (doxyPrEP) for sexually transmitted infections on the microbiome of men who have sex with men on HIV PrEP.

Article Title: Impact of doxycycline pre-exposure prophylaxis (doxyPrEP) for sexually transmitted infections on the microbiome of men who have sex with men on HIV PrEP.

Article References:
Knodel, S., Main, L., DeLeon, M. et al. Impact of doxycycline pre-exposure prophylaxis (doxyPrEP) for sexually transmitted infections on the microbiome of men who have sex with men on HIV PrEP. Nat Commun 16, 6143 (2025). https://doi.org/10.1038/s41467-025-61426-5

Image Credits: AI Generated